Legal & General Group’s Seres Therapeutics MCRB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-499
| Closed | -$7.73K | – | 3473 |
|
|
2024
Q1 | $7.73K | Sell |
499
-225
| -31% | -$4.85K | ﹤0.01% | 3253 |
|
|
2023
Q4 | $20.3K | Sell |
724
-3,560
| -83% | -$93.5K | ﹤0.01% | 3029 |
|
|
2023
Q3 | $204K | Sell |
4,284
-48
| -1% | -$3.66K | ﹤0.01% | 2716 |
|
|
2023
Q2 | $415K | Buy |
4,332
+2,217
| +105% | +$241K | ﹤0.01% | 2520 |
|
|
2023
Q1 | $240K | Buy |
2,115
+127
| +6% | +$13.7K | ﹤0.01% | 2520 |
|
|
2022
Q4 | $223K | Buy |
1,988
+29
| +1% | +$3.89K | ﹤0.01% | 2570 |
|
|
2022
Q3 | $252K | Buy |
1,959
+493
| +34% | +$50.5K | ﹤0.01% | 2540 |
|
|
2022
Q2 | $100K | Buy |
1,466
+14
| +1% | +$1.21K | ﹤0.01% | 2856 |
|
|
2022
Q1 | $207K | Sell |
1,452
-4
| -0.3% | -$615 | ﹤0.01% | 2653 |
|
|
2021
Q4 | $242K | Buy |
1,456
+2
| +0.1% | +$318 | ﹤0.01% | 2640 |
|
|
2021
Q3 | $202K | Buy |
1,454
+677
| +87% | +$132K | ﹤0.01% | 2690 |
|
|
2021
Q2 | $371K | Buy |
777
+65
| +9% | +$27.4K | ﹤0.01% | 2396 |
|
|
2021
Q1 | $294K | Sell |
712
-25
| -3% | -$11.5K | ﹤0.01% | 2383 |
|
|
2020
Q4 | $361K | Buy |
737
+416
| +130% | +$244K | ﹤0.01% | 2319 |
|
|
2020
Q3 | $182K | Sell |
321
-41
| -11% | -$13.6K | ﹤0.01% | 2374 |
|
|
2020
Q2 | $34K | Buy |
362
+87
| +32% | +$7.63K | ﹤0.01% | 2838 |
|
|
2020
Q1 | $20K | Sell |
275
-104
| -27% | -$6.97K | ﹤0.01% | 2914 |
|
|
2019
Q4 | $26K | Buy |
379
+74
| +24% | +$5.49K | ﹤0.01% | 3107 |
|
|
2019
Q3 | $24K | Buy |
305
+136
| +80% | +$8.99K | ﹤0.01% | 3072 |
|
|
2019
Q2 | $10K | Hold |
169
| – | – | ﹤0.01% | 3359 |
|
|
2019
Q1 | $23K | Hold |
169
| – | – | ﹤0.01% | 3047 |
|
|
2018
Q4 | $15K | Hold |
169
| – | – | ﹤0.01% | 3182 |
|
|
2018
Q3 | $26K | Hold |
169
| – | – | ﹤0.01% | 3105 |
|
|
2018
Q2 | $29K | Hold |
169
| – | – | ﹤0.01% | 3037 |
|
|
2018
Q1 | $25K | Sell |
169
-70
| -29% | -$13.4K | ﹤0.01% | 3049 |
|
|
2017
Q4 | $48K | Sell |
239
-57
| -19% | -$11.7K | ﹤0.01% | 2880 |
|
|
2017
Q3 | $96K | Buy |
296
+31
| +12% | +$8.47K | ﹤0.01% | 2678 |
|
|
2017
Q2 | $60K | Hold |
265
| – | – | ﹤0.01% | 2857 |
|
|
2017
Q1 | $59K | Hold |
265
| – | – | ﹤0.01% | 2819 |
|
|
2016
Q4 | $52K | Buy |
265
+121
| +84% | +$26.4K | ﹤0.01% | 2881 |
|
|
2016
Q3 | $35K | Hold |
144
| – | – | ﹤0.01% | 2681 |
|
|
2016
Q2 | $84K | Buy |
144
+66
| +85% | +$38.7K | ﹤0.01% | 2194 |
|
|
2016
Q1 | $40K | Hold |
78
| – | – | ﹤0.01% | 2504 |
|
|
2015
Q4 | $55K | Buy |
+78
| New | +$51.3K | ﹤0.01% | 2411 |
|
Other funds holding MCRB
FP
TCM
Legal & General Group's MCRB Position: Q2 2024 in Review
Legal & General Group sold out of Seres Therapeutics (MCRB) in Q2 2024, closing a stake of 499 shares — an estimated $7.73K sold.
Legal & General Group first reported a position in MCRB in Q4 2015 and held it in 34 quarters. The position peaked at $415K in Q2 2023. 93 funds tracked by Wall St. Rank hold MCRB as of Q2 2024.
- Legal & General Group reported no remaining Seres Therapeutics position as of Q2 2024 after selling out during the quarter.
- Legal & General Group sold 499 Seres Therapeutics shares in Q2 2024, an estimated $7.73K.
- Legal & General Group first reported a position in Seres Therapeutics in Q4 2015 and held it in 34 quarters.
- Legal & General Group's Seres Therapeutics position peaked at $415K in Q2 2023.
- 93 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2024.
Based on Legal & General Group's 13F filing for Q2 2024, filed 14 Aug 2024.